News|Articles|November 18, 2026

Q&A: Strategies for Protecting Skin in Winter, With Jeanine B. Downie, MD

Fact checked by: Tim Smith
Listen
0:00 / 0:00

Key Takeaways

  • Winter UV risk persists via consistent UVA, reflection off snow/ice, and penetration through clouds and glass, supporting daily broad-spectrum sunscreen and adjunctive physical barriers.
  • Earlier detection is compromised by patient underinspection and atypical presentations; clinicians should normalize annual full-body exams, prompt interim evaluations, and serial photo documentation of evolving lesions.
SHOW MORE

For Healthy Skin Month, a dermatologist discusses winter sun protection, overlooked patients in skin cancer screening, bemotrizinol, and AI in detection.

Key Takeaways:

  • Downie said UV exposure continues through winter, so daily broad-spectrum SPF 30 or higher should be a year-round habit.
  • She recommended annual full-body skin exams that include low-sun areas like the palms, soles, and nails, which matters especially for patients with skin of color.
  • She called bemotrizinol and AI detection tools developments to watch, but said neither replaces sun protection basics or a dermatologist’s exam.

As temperatures drop during National Healthy Skin Month in November, many patients stop thinking about sun protection. Jeanine B. Downie, MD, a dermatologist practicing in New Jersey and a spokesperson for The Skin Cancer Foundation, spoke with the team about why winter does not lower the risk from UV exposure. She also discusses where she sees clinicians and patients missing chances to catch skin cancer early, and the simple habit she has recommended to patients for 3 decades.

Downie also addresses the patient groups she considers most overlooked in screening and prevention, at a time when patients with skin of color are more likely to be diagnosed with melanoma at advanced stages.¹ She shares her perspective on 2 developments clinicians should be ready to discuss in the coming year: the US Food and Drug Administration (FDA)’s June 2026 decision on bemotrizinol, the first new sunscreen active ingredient in decades,² and the growing role of artificial intelligence (AI) in lesion detection.

Dermatology Times: Healthy Skin Month lands in November, when sun protection tends to fall off patients’ radar. What message do you most want dermatologists to reinforce with patients during the colder months, and why does year-round photoprotection still matter?

Jeanine B. Downie, MD: I want patients of every race, ethnicity and skin tone to understand that sun protection is a year-round commitment, not a habit reserved for summer vacations or days at the beach. Even when temperatures drop or the sun is less visible, ultraviolet (UV) radiation, which causes 90 percent of all skin cancers, still affects your skin. UV rays still cause sunburn during the colder months, particularly when they reflect off of snow and ice, increasing exposure from both above and below. Also, UVA rays, which do cause DNA damage to the skin, remain relatively consistent throughout the year and can penetrate clouds, fog and glass.

Dermatologists encourage patients to maintain a simple, consistent routine regardless of the season. The Skin Cancer Foundation’s Photobiology Committee recommends using a broad-spectrum sunscreen with an SPF of 30 or higher every day, and SPF 50 or higher for extended outdoor activities. I personally recommend that people wear sunscreen in their homes as well as when they are outdoors and I strongly recommend sunscreens that have blue light protection (high energy visible light) as well as infra-red protection, which is heat. Patients should also seek shade, wear protective clothing, a wide-brimmed hat and UV-blocking sunglasses. It is important to remember that sun damage accumulates over a lifetime, even during everyday activities such as walking the dog, commuting or running errands. And never use indoor tanning beds, which can emit UV radiation 15 times stronger than the midday sun.

Consistent protection helps reduce cumulative UV exposure and, ultimately, the risk of skin cancer. And it’s important to remember that your skin cancer risk is high. Skin cancer incidence is higher than all other cancers combined.

Dermatology Times: What are the most common missed opportunities you see for catching skin cancer early, and what can dermatologists and primary care clinicians do differently during routine visits to close those gaps?

Jeanine B. Downie, MD: One of the biggest missed opportunities is failing to recognize that skin cancer can develop anywhere on the body, including areas that patients may not routinely examine. Patients may assume that a spot is harmless because it does not hurt or bleed, or they wait until a mole becomes noticeably concerning before seeking medical attention. However, skin cancer does not always present as a traditional dark mole. Any spot that is new, changing or unusual should be evaluated by a dermatologist. Early detection is critical because 99 percent of skin cancers are easily curable when detected early.

Dermatologists and primary care clinicians should make skin health part of routine conversations with patients, asking about new or changing spots and encouraging regular professional skin examinations. They can encourage their patients to document suspicious spots with photographs so that they can monitor changes over time and bring them to their dermatologist’s attention. The Skin Cancer Foundation recommends that adults receive full-body professional skin examinations annually. And patients should not wait for their next annual appointment if they notice something concerning.

Dermatology Times: Many patients know they should wear sunscreen and do self-exams but don’t follow through. What counseling strategies have you found actually change behavior, and how does The Skin Cancer Foundation support clinicians in that effort?

Jeanine B. Downie, MD: I think one of the most effective approaches is to make prevention feel manageable, rather than overwhelming. Instead of giving patients a long list of recommendations, I encourage them to incorporate sun protection into habits they already have. For the last 30 years, I have recommended that my patients put sunscreen next to their toothbrush or deodorant. And that seems to help them remember to wear it. Patients can also use their phones to set monthly reminders for skin self-examinations. The goal is to make these behaviors part of the everyday routine rather than something they only think about when they are spending a full day outdoors.

The Skin Cancer Foundation offers several resources that clinicians can incorporate into patient education, including medically reviewed brochures about skin cancer prevention and early detection, monthly skin self-examination instructions and its Seal of Recommendation, which helps consumers identify products that meet sun protection standards established by The Skin Cancer Foundation’s Photobiology Committee.

Dermatology Times: Which patient groups do you feel are most overlooked when it comes to skin cancer screening and prevention, including patients with skin of color who are often diagnosed at later stages, and how should clinicians tailor their approach?

Jeanine B. Downie, MD: Anyone with skin of any skin tone can get skin cancer. There is a persistent misconception that people with darker skin tones do not develop skin cancer or do not need the same level of sun protection and screening. Skin cancer represents 1 to 2 percent of all cancers in Black people, approximately 2 to 4 percent of all cancers in Asian people and 4 to 5 percent of all cancers in Hispanic people.

Unfortunately, when skin cancer does occur in people with darker skin tones it is more likely to be diagnosed at a later stage, when it is more difficult to treat. Black patients are more than three times as likely to be diagnosed with late-stage melanoma as non-Hispanic white patients. Black patients have an estimated five-year melanoma survival rate of 70 percent, versus 94 percent for white patients and are more than three times as likely to be diagnosed with melanoma at a late stage than non-Hispanic white patients. 52 percent of non-Hispanic Black patients and 26 percent of Hispanic patients receive an initial diagnosis of advanced-stage melanoma, versus 16 percent of non-Hispanic white patients.

An important part of improving early detection is educating both patients and health care providers about where skin cancer often develops on darker skin. Melanoma in Black patients frequently occurs in areas that receive little sun exposure, including the palms of hands, soles of feet and underneath or around the nails. These areas might be overlooked during self-examinations and clinical evaluations. Clinicians should emphasize that skin cancer screening is important for everyone and ensure that examinations are comprehensive, regardless of a patient’s skin tone. I would also encourage clinicians to discuss individual risk factors, including personal and family history, previous sunburns, tanning bed use, and cumulative UV exposure.

Other populations that are in need of special attention include older adults with years of accumulated sun exposure, organ transplant recipients and outdoor workers. Research conducted by the World Health Organization and International Labour Organization found that exposure to UV radiation while working outdoors increases the risk of nonmelanoma skin cancer by 60 percent. Additionally, in the U.S., about 50 percent of outdoor workers reported getting sunburn, according to a survey by the American Academy of Dermatology. UV exposure that leads to sunburn has been proven to play a strong role in melanoma incidence.

Dermatology Times: From new sunscreen filters and AI-assisted lesion detection to evolving screening recommendations, what developments are you most watching in skin cancer prevention, and what should clinicians be prepared to discuss with patients in the coming year?

Jeanine B. Downie, MD: Two developments worth watching are advancements in sunscreen formulations and the growing role of technology in skin cancer detection. In June of 2026, the U.S. Food and Drug Administration approved bemotrizinol (BEMT). This is the first new sunscreen active ingredient approved for use in the United States in more than 25 years. This is an important milestone for sun protection innovation because expanding the range of available sunscreen ingredients may provide manufacturers with additional formulation options and potentially encourage more consistent sunscreen use. However, I would emphasize that the fundamentals of sun protection remain unchanged. Patients should look for broad-spectrum protection and reapply every two hours or after swimming or sweating.

I am also interested in the role of artificial intelligence in early detection. These tools should be viewed as potential aids to clinical decision-making rather than replacements for a dermatologist’s examination and judgment. Currently, AI can misdiagnose many different skin conditions, including skin cancers. I respectfully tell my patients that AI is not a substitute for a dermatologist’s clinical skill, training, and judgement. As these technologies continue to develop, clinicians should remain informed about their capabilities and limitations while reinforcing the importance of professional skin examinations and monthly self-checks. Ultimately, the focus for patients should continue to be on skin cancer prevention and early detection. Skin cancer is 90 percent preventable with a good UV-protection strategy and 99 percent treatable when caught early. The Skin Cancer Foundation urges the public and the health care community to continue to make best efforts to share this message so that we can continue to work together to reduce incidence of skin cancer.

References

  1. American Academy of Dermatology. Largest study on racial differences in men with melanoma shows men with skin of color have lowest survival rates. Published July 11, 2023. Accessed November 18, 2026. https://www.aad.org/news/melanoma-study-men-skin-of-color-lowest-survival-rates
  2. HCPLive. FDA adds bemotrizinol as first new sunscreen ingredient in decades. https://www.hcplive.com/view/fda-adds-bemotrizinol-first-new-sunscreen-ingredient-decades. Published June 9, 2026. Accessed November 18, 2026

Related to this article

TanPrevent and the Case for Preventing Thousands of Melanomas
Learn why indoor tanning remains a preventable source of melanoma, what research suggests about why some patients experience difficulty stopping, and how a clinical pilot called TanPrevent could connect education with follow-up support to help them quit and stay quit.